retinal vein occlusion

Data support adding suprachoroidal injection to anti-VEGF for RVOResults from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Study tracks clinical use of dexamethasone implant for DMEA 6-month analysis from the REINFORCE study of the dexamethasone intravitreal implant Ozurdex found an average of one- to two-line vision gains and no new safety concerns.
4 treatment strategies for managing retinal vein occlusions
4 treatment strategies for managing retinal vein occlusionsAlthough much progress has been made in treating retinal vein occlusions, much still needs to be done. Julia Haller, MD, described the four-step, evidence-based approach that she uses to treat these patients
A clinical perspective of neovascular glaucomaNeovascular glaucoma is a potentially devastating ocular consequence of pathologic neovascularization of intraocular tissue. The symptoms include vision loss caused by both the underlying etiology (such as retinal vascular disease) as well as increased intraocular pressure (IOP), often accompanied by corneal edema, hyphema, or vitreous hemorrhage.
Novel strategies considered for treating, preventing RVO
Novel strategies considered for treating, preventing RVOThe advent of anti-vascular endothelial growth factor (VEGF) therapy has been a tremendous advance for the treatment of retinal vein occlusion (RVO), but many other opportunities exist, said Joan W. Miller, MD.
Retinal vein occlusion treatment undergoes paradigm shift with pharmacotherapyBased on findings from a series of clinical trials in recent years, pharmacotherapy has supplanted both laser photocoagulation and a watchful waiting approach as the first-line therapy for retinal vein occlusion.
FDA approves Eylea for all forms of macular edema after retinal vein occlusionThe U.S. Food and Drug Administration (FDA) recently approved Eylea (afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.
RETAIN: Mixed results for BRVO/CRVO with ranibizumab
RETAIN: Mixed results for BRVO/CRVO with ranibizumabThe RETAIN Study of the effect of retinal vein occlusion (RVO) treated with ranibizumab injections found good visual acuity results in patients with branch RVO.
Retina drug therapies ever evolvingMedical advances run gamut from AMD to symptomatic vitreomacular adhesion